The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study
Garth Funston, Willie Hamilton, Gary Abel, Emma J Crosbie, Brian Rous, Fiona M Walter
PLOS Medicine | PUBLIC LIBRARY SCIENCE | Published : 2020
BACKGROUND: The serum biomarker cancer antigen 125 (CA125) is widely used as an investigation for possible ovarian cancer in symptomatic women presenting to primary care. However, its diagnostic performance in this setting is unknown. We evaluated the performance of CA125 in primary care for the detection of ovarian and non-ovarian cancers. METHODS AND FINDINGS: We studied women in the United Kingdom Clinical Practice Research Datalink with a CA125 test performed between 1 May 2011-31 December 2014. Ovarian and non-ovarian cancers diagnosed in the year following CA125 testing were identified from the cancer registry. Women were categorized by age: <50 years and ≥50 years. Conventional measur..View full abstract
Awarded by Cancer Research UK
Awarded by National Institute of Health Research (NIHR) School of Primary Care Research
Awarded by NIHR Manchester Biomedical Research Centre
This research arises from the CanTest Collaborative, which is funded by Cancer Research UK [C8640/A23385], of which GF is Clinical Research Fellow, GA is the Senior Statistician, and WH and FMW are Directors. The study was also funded by the National Institute of Health Research (NIHR) School of Primary Care Research [FR17 424] (GF, FMW). EJC is supported through the NIHR Manchester Biomedical Research Centre [ISBRC-1215-20007]. The funders of this study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.